As of 2026-05-26, the Intrinsic Value of Dechra Pharmaceuticals PLC (DPH.L) is 444.51 GBP. This DPH.L valuation is based on the model Discounted Cash Flows (Growth Exit 10Y). With the current market price of 3,866.00 GBP, the upside of Dechra Pharmaceuticals PLC is -88.50%.
The range of the Intrinsic Value is 121.18 - 1,716.15 GBP
Based on its market price of 3,866.00 GBP and our intrinsic valuation, Dechra Pharmaceuticals PLC (DPH.L) is overvalued by 88.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (310.07) - (93.99) | (266.27) | -106.9% |
| DCF (Growth 10y) | 121.18 - 1,716.15 | 444.51 | -88.5% |
| DCF (EBITDA 5y) | 549.20 - 924.07 | 690.81 | -82.1% |
| DCF (EBITDA 10y) | 909.63 - 1,627.95 | 1,186.98 | -69.3% |
| Fair Value | -122.53 - -122.53 | -122.53 | -103.17% |
| P/E | (456.80) - (488.66) | (460.72) | -111.9% |
| EV/EBITDA | 353.44 - 2,558.05 | 1,292.70 | -66.6% |
| EPV | 628.45 - 1,040.26 | 834.35 | -78.4% |
| DDM - Stable | (247.85) - (1,097.64) | (672.74) | -117.4% |
| DDM - Multi | 233.89 - 833.63 | 368.85 | -90.5% |
| Market Cap (mil) | 4,401.32 |
| Beta | 1.15 |
| Outstanding shares (mil) | 1.14 |
| Enterprise Value (mil) | 4,831.43 |
| Market risk premium | 5.98% |
| Cost of Equity | 8.47% |
| Cost of Debt | 4.60% |
| WACC | 7.95% |